Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide is a synthetic small molecule with the molecular formula C20H20ClN3S and a molecular weight of approximately 369.9 g/mol[1][6][7]. It is primarily used as a research tool and not approved for clinical or therapeutic use[2][3]. The compound is known to act as an inhibitor of nitric oxide synthase (NOS), including isoforms such as neuronal NOS (nNOS/NOS1), endothelial NOS (eNOS/NOS3), and inducible NOS (iNOS)[1]. Its mechanism involves binding to the active site of these enzymes, thereby inhibiting the production of nitric oxide, which plays roles in neurotransmission, vascular regulation, and immune response. The compound has been studied structurally in protein-ligand complexes but has no reported clinical development or approved indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide.